CSI Market
Sign In | Register

Ligand Pharmaceuticals Incorporated (LGND) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access LGND Annual Income Statement →
By examining income statement figures across successive periods, users can identify shifts in Ligand Pharmaceuticals Incorporated's profitability and expense structure.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Quarterly Report, GAAP in USD millions
ITEM 		(Jun 30 2026)
Q2 2026 		(Mar 31 2026) (Dec 31 2025) (Sep 30 2025) (Jun 30 2025)
Revenues
Revenue From Contract With Customer Excluding Assessed Tax63.69
Total Revenue63.69
Costs & Expenses
Cost of Goods and Services Sold8.10
Gross Profit55.60
Selling, Administration, Marketing29.12
Depreciation & Amortization0.00
Research and Development Expense14.67
Impairment of Intangible Assets (Excluding Goodwill)0.00
Other Operating Expense / -Income3.21
Total operating costs including COS55.10
Operating income / -loss8.59
Net Interest Expense / -Income0.00
Loss / -Gain on Investment19.05
Other loss / -income0.00
Total costs & expenses0.00
Income & Taxes
Income / -loss before income taxes64.30
Income taxes expenses / -benefit15.80
Income after income taxes48.51
Income / -loss from continuing operations48.51
Net income / -loss48.51
Income / -loss to shareholder48.51
EBIT64.30
EBITD72.52
EBITDA73.34
Earnings Per Share
Basic EPS (excl. extra items)2.42
Basic Net EPS2.42
Basic shares outstanding (Mill. of Units)20.06
Diluted Net EPS2.22
Diluted average shares (Mill. of Units)21.84
4 historic quarters locked

Sign in to unlock the full Ligand Pharmaceuticals Incorporated income statement history.

Sign In Create Free Account

About Ligand Pharmaceuticals Inc Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: August 7, 2026
  • Original filing: lgnd-20260630.htm

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.